<DOC>
	<DOCNO>NCT00874874</DOCNO>
	<brief_summary>RATIONALE : Sorafenib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase II trial study well sorafenib work treat patient angiosarcoma locally advanced , metastatic , unable remove surgery .</brief_summary>
	<brief_title>Sorafenib Treating Patients With Angiosarcoma That Locally Advanced , Metastatic , Unable Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine rate non-progression 9 month patient unresectable , locally advanced , metastatic angiosarcoma treat sorafenib tosylate . Secondary - Determine rate non-progression 60 , 120 , 180 day . - Determine median time progression . - Determine overall survival . - Determine best response rate . - Determine clinical biological factor predict clinical benefit . - Evaluate tolerability NCI CTCAE v3.0 . - Correlate efficacy plasma expression gene implicate control angiogenesis . - Explore tumor expression gene tissue tumor bank . OUTLINE : This multicenter study . Patients stratify accord disease type ( cutaneous angiosarcoma [ scalp , breast , soft tissue ] vs visceral angiosarcoma ) . All patient receive oral sorafenib tosylate twice daily 9 month absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Hemangiosarcoma</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm angiosarcoma Locally advance metastatic disease Unresectable disease No Kaposi sarcoma , hemangiopericytoma , hemangioendothelioma Measurable tumor least 1 measurable lesion RECIST criterion Tumor previously irradiate area must show progression No brain metastasis meningeal tumor ( symptomatic asymptomatic ) PATIENT CHARACTERISTICS : WHO performance status 02 Life expectancy ≥ 3 month WBC ≥ 3,000/mm³ ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9 g/dL PT INR aPTT ≤ 1.5 time upper limit normal ( ULN ) Anticoagulation treatment heparin vitamin K allow criterion meet Liver transaminase ≤ 2.5 time ULN ( ≤ 5 time ULN presence liver metastasis ) Total bilirubin ≤ 1.5 time ULN Serum creatinine ≤ 1.5 time ULN Amylase lipase ≤ 1.5 time ULN Not pregnant nursing Weight loss predisease weight &lt; 20 % past 12 month Able swallow No active ischemic coronary artery disease No myocardial infarction within past 6 month No NYHA class IIIIV cardiac failure No uncontrolled hypertension No coagulopathy No active uncontrolled peptic ulcer No patient renal dialysis No active bacterial fungal infection &gt; CTCAE v3.0 grade 2 No HIV hepatitis B C positivity No chronic unstable illness could jeopardize patient safety compliance No progressive malignant tumor No known suspect allergy sorafenib tosylate No psychological , familial , social , geographic situation preclude clinical follow No patient deprive liberty guardianship No cardiac arrhythmia require antiarrhythmic medication ( except betablockers digoxin chronic atrial fibrillation ) No epilepsy require antiepileptic drug PRIOR CONCURRENT THERAPY : See Patient Characteristics No prior organ peripheral stem cell transplantation No 2 prior line chemotherapy At least 28 day since prior treatment ( systemic major surgery ) No concurrent therapy another malignancy No concurrent CYP3A inducer ( e.g. , rifampicin , St. John wort , phenytoin , carbamazepine , phenobarbital , dexamethasone )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>adult angiosarcoma</keyword>
</DOC>